X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will support NRG's lead drug discovery programme and the development of a novel treatment for Parkinson’s. NRG has discovered novel second-generation, mPTP inhibitors that are brain penetrant, for use in the treatment of chronic neurodegenerative disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding February 22, 2023
Details:
The Series A proceeds will be used to advance the company's potential first-in-class brain-penetrant small molecules through IND-enabling studies.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 09, 2022
Details:
The funding will support the NRG pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease (PD) and motor neuron disease (MND).
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Funding May 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
